Malignant News and Research

RSS

QuantRx Biomedical launches its new flagship POC diagnostic reader device at MEDICA 2009

QuantRx® Biomedical Corporation, a broad-based diagnostic company focused on the development and commercialization of innovative diagnostic products, announced today the successful debut of its new flagship point-of-care (POC) diagnostic reader device, Q-Reader™, at MEDICA 2009 on November 18-21, 2009, in Düsseldorf, Germany.

8 Dec 2009

Ambit Biosciences presents study results of its AC220 FLT3 inhibitor for AML

Ambit Biosciences Corporation announced today that preliminary results from a clinical trial of its lead product candidate, AC220, in acute myeloid leukemia (AML) were presented at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans. AC220 is a novel, orally available, small molecule that was expressly optimized as a FMS-like tyrosine kinase-3 (FLT3) inhibitor for the treatment of AML.

8 Dec 2009

JAK2 inhibitor can control myelofibrosis, report researchers

A first-in-its class oral medication provides significant and durable relief for patients with a rare, debilitating and lethal bone marrow disorder called myelofibrosis, researchers at The University of Texas M. D. Anderson Cancer Center reported today at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

Social isolation and stress can raise breast cancer risk

Social isolation and related stress could contribute to human breast cancer susceptibility, research from a rat model designed at the University of Chicago to identify environmental mechanisms contributing to cancer risk shows.

8 Dec 2009

Gloucester Pharmaceuticals to be acquired by Celgene

Celgene Corporation and Gloucester Pharmaceuticals Inc., a privately held pharmaceutical company, announced a definitive merger agreement under which Celgene Corporation will acquire Gloucester Pharmaceuticals. Celgene says the acquisition will continue to advance its leadership position in the development of disease-altering therapies through innovative approaches for patients with rare and debilitating blood cancers.

7 Dec 2009

Positive data from Gloucester Pharmaceuticals' ISTODAX study presented at the ASH meeting

Gloucester Pharmaceuticals announced today the presentation of positive data from an analysis of ISTODAX® (romidepsin) in a subset of patients from Gloucester’s registration study in cutaneous T-cell lymphoma (CTCL) at the 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, LA.

7 Dec 2009

Vitamin D supplements may aid in treating cancer

The findings support the growing association between vitamin D and cancer risk and outcomes, and suggest that vitamin D supplements might help even those patients already diagnosed with some forms of cancer, says Dr. Drake.

7 Dec 2009

New diagnostic guidelines for inexpensive and accurate detection of lung cancer

A simple, inexpensive computer tool that measures volume changes in the size of suspicious nodules in the lungs picked up by a CT scanner can rule out non-cancerous ones with almost perfect accuracy and enable doctors to diagnose true cancers with fewer, less expensive and less invasive tests.

5 Dec 2009

'Twist' gene plays a key role in the development of breast cancer

Working with mice, scientists at Johns Hopkins publishing in the December issue of Neoplasia have shown that a protein made by a gene called "Twist" may be the proverbial red flag that can accurately distinguish stem cells that drive aggressive, metastatic breast cancer from other breast cancer cells.

5 Dec 2009

Cancer-free status does not lead to resumption of smoking among former smokers

Assurance of a cancer-free status did not prompt people participating in a long-term computerized tomography (CT) lung-cancer screening program to pick up their cigarettes again, researchers wrote in a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

4 Dec 2009

Osseon Therapeutics' Osseoflex and Osseoflex DR systems receive Canadian Medical Device Licenses

Osseon Therapeutics announced today that its Osseoflex (steerable and curvable bone cement delivery needle) and Osseoflex DR (steerable and curvable bone drill) systems for percutaneous vertebral augmentation received Canadian Medical Device Licenses from Health Canada for marketing and clinical use in Canada.

4 Dec 2009

Protein plays a key role in cancer and DNA repair

A protein that plays a key role in copying DNA also plays a vital role in repairing breaks in it, UC Davis scientists have found. The work is helping researchers understand how cancer cells can resist radiation and chemotherapy, as well as how cells become cancerous in the first place.

4 Dec 2009

TGen scientists win $1,000 prize for best scientific paper presented at BIBM09

A team of scientists at the Translational Genomics Research Institute (TGen) won a $1,000 prize for best scientific paper presented at BIBM09, a premier bioinformatics and biomedicine conference.

3 Dec 2009

Videos can help overcome communication barriers and influence patients' choices for medical care

Patients with terminal brain cancer who watched a brief video illustrating options for end-of-life care were significantly more likely to indicate a preference for comfort measures only than were patients who listened to a verbal description of treatment choices.

3 Dec 2009

GammaL c device provides accurate lesion localization and facilitates needle-guided biopsy

Breast-Specific Gamma Imaging (BSGI) is a molecular breast imaging technique increasingly being used in the diagnostic workup of patients with indeterminate mammograms and has demonstrated the ability to detect cancers missed by mammography and ultrasound.

2 Dec 2009

Novel approach to detect flaws in defense against breast cancer earns Era of Hope Scholar Award

A novel approach to detecting and targeting flaws in first line of defense against cancer has earned an Era of Hope Scholar Award from the U.S. Department of Defense for a scientist at The University of Texas M. D. Anderson Cancer Center.

2 Dec 2009

Researchers discover ability of stem cells in brain cancer glioma to resist radiation therapy

Duke University Medical Center researchers have figured out how stem cells in the malignant brain cancer glioma may be better able to resist radiation therapy. And using a drug to block a particular signaling pathway in these cancer stem cells, they were able to kill many more glioma cells with radiation in a laboratory experiment.

2 Dec 2009

Human Melanoma Research Team pursuing identification of anti-tumor prognostic markers and drugs

The constant increase in the rate of cutaneous melanoma over recent years and its resistance to anti-tumour pharmaceutical drugs has meant that the study of cutaneous melanoma is one of the greatest scientific challenges in the field of cancer. The Human Melanoma research team at the University of the Basque Country (UPV/EHU) is focusing on this study.

2 Dec 2009

BSGI effective in detecting malignant or high-risk lesions in patients with negative mammographic findings

Breast-Specific Gamma Imaging (BSGI) significantly contributes to the detection of malignant or high-risk lesions in patients with negative or indeterminate mammographic findings, according to results of a multicenter study presented today at the annual meeting of the Radiological Society of North America (RSNA).

2 Dec 2009

FDA approves Schering-Plough's New Drug Application for ZEGERID OTC capsules

Santarus, Inc., a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Schering-Plough HealthCare Products, Inc.’s, New Drug Application (NDA) for ZEGERID OTC™ Capsules (omeprazole/sodium bicarbonate) with a dosage strength of 20 mg of omeprazole for over-the-counter (OTC) treatment of frequent heartburn.

2 Dec 2009

Malignant News and Research

QuantRx Biomedical launches its new flagship POC diagnostic reader device at MEDICA 2009

Ambit Biosciences presents study results of its AC220 FLT3 inhibitor for AML

JAK2 inhibitor can control myelofibrosis, report researchers

Social isolation and stress can raise breast cancer risk

Gloucester Pharmaceuticals to be acquired by Celgene

Positive data from Gloucester Pharmaceuticals' ISTODAX study presented at the ASH meeting

Vitamin D supplements may aid in treating cancer

New diagnostic guidelines for inexpensive and accurate detection of lung cancer

'Twist' gene plays a key role in the development of breast cancer

Cancer-free status does not lead to resumption of smoking among former smokers

Osseon Therapeutics' Osseoflex and Osseoflex DR systems receive Canadian Medical Device Licenses

Protein plays a key role in cancer and DNA repair

TGen scientists win $1,000 prize for best scientific paper presented at BIBM09

Videos can help overcome communication barriers and influence patients' choices for medical care

GammaL c device provides accurate lesion localization and facilitates needle-guided biopsy

Novel approach to detect flaws in defense against breast cancer earns Era of Hope Scholar Award

Researchers discover ability of stem cells in brain cancer glioma to resist radiation therapy

Human Melanoma Research Team pursuing identification of anti-tumor prognostic markers and drugs

BSGI effective in detecting malignant or high-risk lesions in patients with negative mammographic findings

FDA approves Schering-Plough's New Drug Application for ZEGERID OTC capsules

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News